enzastaurin + gemcitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Neoplasm
Conditions
Pancreatic Neoplasm
Trial Timeline
Dec 1, 2005 → May 1, 2008
NCT ID
NCT00267020About enzastaurin + gemcitabine
enzastaurin + gemcitabine is a phase 2 stage product being developed by Eli Lilly for Pancreatic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT00267020. Target conditions include Pancreatic Neoplasm.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00267020 | Phase 2 | Completed |
Competing Products
20 competing products in Pancreatic Neoplasm